How advances in immunology provide insight into improving vaccine efficacy

Mark Slifka, Ian Amanna

    Research output: Contribution to journalArticle

    36 Citations (Scopus)

    Abstract

    Vaccines represent one of the most compelling examples of how biomedical research has improved society by saving lives and dramatically reducing the burden of infectious disease. Despite the importance of vaccinology, we are still in the early stages of understanding how the best vaccines work and how we can achieve better protective efficacy through improved vaccine design. Most successful vaccines have been developed empirically, but recent advances in immunology are beginning to shed new light on the mechanisms of vaccine-mediated protection and development of long-term immunity. Although natural infection will often elicit lifelong immunity, almost all current vaccines require booster vaccination in order to achieve durable protective humoral immune responses, regardless of whether the vaccine is based on infection with replicating live-attenuated vaccine strains of the specific pathogen or whether they are derived from immunization with inactivated, non-replicating vaccines or subunit vaccines. The form of the vaccine antigen (e.g., soluble or particulate/aggregate) appears to play an important role in determining immunogenicity and the interactions between dendritic cells, B cells and T cells in the germinal center are likely to dictate the magnitude and duration of protective immunity. By learning how to optimize these interactions, we may be able to elicit more effective and long-lived immunity with fewer vaccinations.

    Original languageEnglish (US)
    Pages (from-to)2948-2957
    Number of pages10
    JournalVaccine
    Volume32
    Issue number25
    DOIs
    StatePublished - May 23 2014

    Fingerprint

    Allergy and Immunology
    immunology
    Vaccines
    vaccines
    Immunity
    immunity
    live vaccines
    Vaccination
    Attenuated Vaccines
    Subunit Vaccines
    Germinal Center
    subunit vaccines
    biomedical research
    vaccine development
    dendritic cells
    cell aggregates
    Humoral Immunity
    Infection
    humoral immunity
    infection

    Keywords

    • Antibody
    • Immunological memory
    • Protection
    • Vaccination

    ASJC Scopus subject areas

    • Molecular Medicine
    • Immunology and Microbiology(all)
    • Infectious Diseases
    • Public Health, Environmental and Occupational Health
    • veterinary(all)

    Cite this

    How advances in immunology provide insight into improving vaccine efficacy. / Slifka, Mark; Amanna, Ian.

    In: Vaccine, Vol. 32, No. 25, 23.05.2014, p. 2948-2957.

    Research output: Contribution to journalArticle

    Slifka, Mark ; Amanna, Ian. / How advances in immunology provide insight into improving vaccine efficacy. In: Vaccine. 2014 ; Vol. 32, No. 25. pp. 2948-2957.
    @article{347a42e80caa4b9db071a2d0c0459f8e,
    title = "How advances in immunology provide insight into improving vaccine efficacy",
    abstract = "Vaccines represent one of the most compelling examples of how biomedical research has improved society by saving lives and dramatically reducing the burden of infectious disease. Despite the importance of vaccinology, we are still in the early stages of understanding how the best vaccines work and how we can achieve better protective efficacy through improved vaccine design. Most successful vaccines have been developed empirically, but recent advances in immunology are beginning to shed new light on the mechanisms of vaccine-mediated protection and development of long-term immunity. Although natural infection will often elicit lifelong immunity, almost all current vaccines require booster vaccination in order to achieve durable protective humoral immune responses, regardless of whether the vaccine is based on infection with replicating live-attenuated vaccine strains of the specific pathogen or whether they are derived from immunization with inactivated, non-replicating vaccines or subunit vaccines. The form of the vaccine antigen (e.g., soluble or particulate/aggregate) appears to play an important role in determining immunogenicity and the interactions between dendritic cells, B cells and T cells in the germinal center are likely to dictate the magnitude and duration of protective immunity. By learning how to optimize these interactions, we may be able to elicit more effective and long-lived immunity with fewer vaccinations.",
    keywords = "Antibody, Immunological memory, Protection, Vaccination",
    author = "Mark Slifka and Ian Amanna",
    year = "2014",
    month = "5",
    day = "23",
    doi = "10.1016/j.vaccine.2014.03.078",
    language = "English (US)",
    volume = "32",
    pages = "2948--2957",
    journal = "Vaccine",
    issn = "0264-410X",
    publisher = "Elsevier BV",
    number = "25",

    }

    TY - JOUR

    T1 - How advances in immunology provide insight into improving vaccine efficacy

    AU - Slifka, Mark

    AU - Amanna, Ian

    PY - 2014/5/23

    Y1 - 2014/5/23

    N2 - Vaccines represent one of the most compelling examples of how biomedical research has improved society by saving lives and dramatically reducing the burden of infectious disease. Despite the importance of vaccinology, we are still in the early stages of understanding how the best vaccines work and how we can achieve better protective efficacy through improved vaccine design. Most successful vaccines have been developed empirically, but recent advances in immunology are beginning to shed new light on the mechanisms of vaccine-mediated protection and development of long-term immunity. Although natural infection will often elicit lifelong immunity, almost all current vaccines require booster vaccination in order to achieve durable protective humoral immune responses, regardless of whether the vaccine is based on infection with replicating live-attenuated vaccine strains of the specific pathogen or whether they are derived from immunization with inactivated, non-replicating vaccines or subunit vaccines. The form of the vaccine antigen (e.g., soluble or particulate/aggregate) appears to play an important role in determining immunogenicity and the interactions between dendritic cells, B cells and T cells in the germinal center are likely to dictate the magnitude and duration of protective immunity. By learning how to optimize these interactions, we may be able to elicit more effective and long-lived immunity with fewer vaccinations.

    AB - Vaccines represent one of the most compelling examples of how biomedical research has improved society by saving lives and dramatically reducing the burden of infectious disease. Despite the importance of vaccinology, we are still in the early stages of understanding how the best vaccines work and how we can achieve better protective efficacy through improved vaccine design. Most successful vaccines have been developed empirically, but recent advances in immunology are beginning to shed new light on the mechanisms of vaccine-mediated protection and development of long-term immunity. Although natural infection will often elicit lifelong immunity, almost all current vaccines require booster vaccination in order to achieve durable protective humoral immune responses, regardless of whether the vaccine is based on infection with replicating live-attenuated vaccine strains of the specific pathogen or whether they are derived from immunization with inactivated, non-replicating vaccines or subunit vaccines. The form of the vaccine antigen (e.g., soluble or particulate/aggregate) appears to play an important role in determining immunogenicity and the interactions between dendritic cells, B cells and T cells in the germinal center are likely to dictate the magnitude and duration of protective immunity. By learning how to optimize these interactions, we may be able to elicit more effective and long-lived immunity with fewer vaccinations.

    KW - Antibody

    KW - Immunological memory

    KW - Protection

    KW - Vaccination

    UR - http://www.scopus.com/inward/record.url?scp=84899905951&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84899905951&partnerID=8YFLogxK

    U2 - 10.1016/j.vaccine.2014.03.078

    DO - 10.1016/j.vaccine.2014.03.078

    M3 - Article

    VL - 32

    SP - 2948

    EP - 2957

    JO - Vaccine

    JF - Vaccine

    SN - 0264-410X

    IS - 25

    ER -